Citigroup
ACTU

Citigroup’s Actuate Therapeutics ACTU Stock Holding History

Citigroup’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36K Buy
498
+283
+132% +$1.17K ﹤0.01% 5453
2025
Q4 		$1.32K Sell
215
-45
-17% -$309 ﹤0.01% 5516
2025
Q3 		$1.74K Sell
260
-1,829
-88% -$13.3K ﹤0.01% 5519
2025
Q2 		$12.8K Buy
2,089
+1,440
+222% +$12.6K ﹤0.01% 5149
2025
Q1 		$4.39K Buy
649
+647
+32,350% +$5.19K ﹤0.01% 5292
2024
Q4 		$16 Sell
2
-10,971
-100% -$89.5K ﹤0.01% 5756
2024
Q3 		$81.7K Buy
+10,973
New +$86.9K ﹤0.01% 4861

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's ACTU Position: Q1 2026 in Review

Citigroup increased its Actuate Therapeutics (ACTU) stake by 132% in Q1 2026, buying an estimated $1.17K and bringing the position to 498 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #5453.

Citigroup first reported a position in ACTU in Q3 2024 and has held it in 7 quarters since. The position peaked at $81.7K in Q3 2024. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Citigroup held 498 shares of Actuate Therapeutics worth $1.36K as of Q1 2026.
  • Citigroup bought 283 Actuate Therapeutics shares in Q1 2026, an estimated $1.17K.
  • Actuate Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5453 holding.
  • Citigroup first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Citigroup's Actuate Therapeutics position peaked at $81.7K in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.